Medicus Pharma Reports Strong Skinject Results and Expands Teverelix Pipeline

Apr 16, 2026

Medicus Pharma (NASDAQ: MDCX) is advancing its lead asset Skinject, a non-invasive microneedle-based therapy for basal cell carcinoma, after delivering strong Phase 2 results. The study showed that up to 3 out of 4 patients achieved visual clearance, potentially reducing the need for immediate surgery in one of the most common cancers worldwide.

The company is also progressing Teverelix, a next-generation hormone therapy targeting prostate cancer and other hormone-driven conditions, with additional potential in women’s health. With active FDA engagement, partnering discussions, and AI-driven trial optimization, Medicus is entering a catalyst-rich phase of growth.

#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#Oncology
#ProstateCancer
#WomensHealth
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#AI
#NewsOut